Baird Upgrades LivaNova(LIVN.US) to Buy Rating, Raises Target Price to $66
LivaNova: Strong Buy Rating on Robust Revenue and Earnings Growth Outlook
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
LivaNova (LIVN) Gets a Hold From Barclays
LivaNova Analyst Ratings
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $55
LivaNova Hold Rating Justified by US VNS Reimbursement Uncertainty and Italian Legal Challenges
LivaNova Price Target Cut to $55.00/Share From $57.00 by Baird
Baird Maintains LivaNova(LIVN.US) With Hold Rating, Cuts Target Price to $55
LivaNova Analyst Ratings
Needham Maintains LivaNova(LIVN.US) With Buy Rating, Raises Target Price to $75
Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained
Piper Sandler Maintains LivaNova(LIVN.US) With Buy Rating, Maintains Target Price $75
Piper Sandler Sticks to Their Buy Rating for LivaNova (LIVN)
LivaNova Price Target Raised to $72.00/Share From $70.00 by Stifel
LivaNova Analyst Ratings
Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW) and LivaNova (LIVN)
Stifel Maintains LivaNova(LIVN.US) With Buy Rating, Raises Target Price to $72
LivaNova Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)